Viking Therapeutics: Stock at $32.90 – Analysts Target $93.60

Viking Therapeutics Inc. (VKTX) closed at $32.90 on July 3, 2026, marking a slight gain of 0.61 percent compared to the previous day ($32.70). Trading volume stood at 20,069 shares, with the daily range fluctuating between $31.50 and $33.95.

Analyst Consensus Shows Strong Upside Potential

Financial analysts' ratings are predominantly positive. Of 24 total assessments tracked (as of July 5, 2026), 22 analysts assigned a "Buy" rating and one a "Strong Buy" rating. Only one analyst recommends the stock with "Hold", while no sell recommendations ("Sell" or "Strong Sell") are present.

The average analyst price target is $93.60, with a median target of $95.00. The range of price targets spans from $83.00 to $101.00. Measured against the July 3, 2026 closing price, the median price target represents potential upside of approximately 185 percent.

Technical Indicators Point to Uptrend

The Relative Strength Index (RSI), a momentum indicator that measures overbought or oversold market conditions, stood at 64.84 on July 2, 2026. Values between 30 and 70 are considered neutral, while values above 70 suggest overheating. The current RSI thus lies in positive territory without sending overheating signals.

In preceding trading days between late June and early July, the RSI moved multiple times above the 70 mark, reaching a local high of 75.36 on June 29. Since June 12, when the RSI was at 42.25, a clear uptrend in the indicator is evident.

Business Model Focused on Metabolic Diseases

Viking Therapeutics is a clinical-stage biopharmaceutical company specializing in novel therapies for metabolic and endocrine diseases. The company concentrates on developing drugs tailored to specific receptors and tissues.

The lead candidate in the product portfolio is VK2809, an orally administered, tissue- and receptor-selective agonist of the thyroid hormone receptor beta (TRβ). This drug candidate is currently in Phase IIb studies for treating non-alcoholic steatohepatitis (NASH) in biopsy-confirmed patients as well as non-alcoholic fatty liver disease (NAFLD).

Additional drug candidates in the pipeline include VK5211, a non-steroidal selective androgen receptor modulator (SARM) for patients following non-elective hip fractures, and VK0612 for type 2 diabetes, which is expected to enter Phase IIb studies.

Trading Activity and Market Environment

The trading volume of 20,069 shares on July 3, 2026 is below average for comparable trading days. For comparison: in the previous week, daily volumes sometimes reached six-digit levels. The moderate activity suggests a quiet trading environment, typical for summer months and near holidays.

The stock is traded in US dollars. For investors in the DACH region settling in Swiss francs or euros, currency risks arise that should be considered in the valuation. The current USD/CHF exchange rate and USD/EUR rate affect the actual return in home currency.

Risks and Opportunities in Biotech Investments

Investments in clinical-stage biopharmaceutical companies carry inherent risks. Success depends substantially on the outcomes of ongoing and future clinical trials. Positive trial results can lead to significant stock gains, while setbacks in development or regulatory hurdles can result in substantial losses.

The broad support among analysts and the significant upside potential to the average price target of $93.60 reflect expectations for the product pipeline. The focus on metabolic diseases such as NASH and NAFLD addresses a growing market, as these conditions are increasing globally and currently have only limited therapeutic options.

Technical indicators support the positive assessment, with the RSI pointing to intact upside momentum without the stock appearing overbought in the short term. Price development since mid-June shows stabilization and recovery following a prior weakness phase.